Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

ZD1839 (‘Iressa’), an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently being investigated in clinical trials as a treatment for cancer. ‘Iressa’ is a trademark of the AstraZeneca group of companies. We have previously demonstrated a synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Magné, N, Fischel, J-L, Tiffon, C, Formento, P, Dubreuil, A, Renée, N, Formento, J-L, Francoual, M, Ciccolini, J, Etienne, M-C, Milano, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394392/
https://www.ncbi.nlm.nih.gov/pubmed/12888834
http://dx.doi.org/10.1038/sj.bjc.6601131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394392/
https://www.ncbi.nlm.nih.gov/pubmed/12888834
http://dx.doi.org/10.1038/sj.bjc.6601131

Ejemplares similares